Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors
- PMID: 31493743
- DOI: 10.1016/j.ejmech.2019.111648
Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors
Abstract
Epidermal growth factor receptor (EGFR, also known as HER1) and HER2, prominent members of receptor tyrosine kinase (RTK) superfamily, have been reported as diagnostic or prognostic markers in tumor progression. Based on the importance of molecular hybridization of pyrazoline and thiazole scaffolds in the discovery of potent anticancer agents, new thiazolyl-pyrazoline derivatives (3a-v) were synthesized and screened for their cytotoxic effects on A549 human lung adenocarcinoma, MCF-7 human breast adenocarcinoma and A375 human melanoma cell lines. 1-(4-(4-Fluorophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3c),1-(4-(4-cyanophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3f) and 1-(4-(4-cyanophenyl)thiazol-2-yl)-3-(4-piperidinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3q) were found as the most potent anticancer agents against A549 and MCF-7 cell lines compared to erlotinib. Compound 3q also showed moderate cytotoxic activity against A375 cell line. Moreover, these compounds exert a cancer cell-selective action against Jurkat cell line posing no toxicity on peripheral blood mononuclear cells (PBMCs). In order to enlighten the mechanism of action underlying anticancer activity, compounds 3c, 3f and 3q were investigated for their apoptotic effects on A549 and MCF-7 cell lines and inhibitory potencies against eight different RTKs including EGFR and HER2 compared to erlotinib. The results indicated that compounds 3f and 3q induced apoptosis in both cell lines and showed significant EGFR inhibitory activity with IC50 values of 4.34 ± 0.66 μM and 4.71 ± 0.84 μM, respectively when compared with erlotinib (IC50 = 0.05 ± 0.01 μM). Besides, compound 3f also inhibited HER2 notably with an IC50 value of 2.28 ± 0.53 μM making it a dual EGFR and HER2 inhibitor. Molecular docking studies, which were conducted to support the in vitro assays, pointed out that compound 3f showed high affinity into the ATP binding sites of EGFR and HER2.
Keywords: Apoptosis; Cancer; EGFR; HER2; Molecular docking; Thiazolyl-pyrazoline.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Exploitation of novel pyrazolo[3,4-d]pyrimidine scaffold tethered to thiazole as potential EGFR/HER2 dual kinase inhibitor to overcome lapatinib resistant breast cancer: Design, synthesis, in silico docking and molecular dynamic simulation.Bioorg Chem. 2025 Aug;163:108671. doi: 10.1016/j.bioorg.2025.108671. Epub 2025 Jun 3. Bioorg Chem. 2025. PMID: 40480106
-
Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.Bioorg Med Chem Lett. 2011 Sep 15;21(18):5374-7. doi: 10.1016/j.bmcl.2011.07.010. Epub 2011 Jul 14. Bioorg Med Chem Lett. 2011. PMID: 21802290
-
Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.Drug Des Devel Ther. 2022 May 16;16:1457-1471. doi: 10.2147/DDDT.S356988. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35607598 Free PMC article.
-
2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.Bioorg Chem. 2020 Jun;99:103798. doi: 10.1016/j.bioorg.2020.103798. Epub 2020 Mar 29. Bioorg Chem. 2020. PMID: 32247112 Review.
-
Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.Bioorg Med Chem Lett. 2022 Feb 15;58:128529. doi: 10.1016/j.bmcl.2022.128529. Epub 2022 Jan 7. Bioorg Med Chem Lett. 2022. PMID: 35007724 Review.
Cited by
-
Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling.ACS Omega. 2022 May 18;7(21):17881-17893. doi: 10.1021/acsomega.2c01188. eCollection 2022 May 31. ACS Omega. 2022. PMID: 35664590 Free PMC article.
-
Synthesis and Anticancer Activities of Pyrazole-Thiadiazole-Based EGFR Inhibitors.ACS Omega. 2023 Aug 17;8(34):31500-31509. doi: 10.1021/acsomega.3c04635. eCollection 2023 Aug 29. ACS Omega. 2023. PMID: 37663500 Free PMC article.
-
Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds.Pharmaceuticals (Basel). 2025 Feb 19;18(2):270. doi: 10.3390/ph18020270. Pharmaceuticals (Basel). 2025. PMID: 40006082 Free PMC article.
-
Synthesis, biological evaluation, and in silico studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents.RSC Adv. 2020 Sep 15;10(56):34114-34129. doi: 10.1039/d0ra06799g. eCollection 2020 Sep 10. RSC Adv. 2020. PMID: 35519030 Free PMC article.
-
A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non-Small Cell Lung Cancer.Arch Pharm (Weinheim). 2025 Apr;358(4):e2400992. doi: 10.1002/ardp.202400992. Arch Pharm (Weinheim). 2025. PMID: 40194950 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous